{"id":"pf-06439535-cn","rwe":[],"tags":[],"phase":"discontinued","safety":{"boxedWarnings":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":[],"specialPopulations":{"Pregnancy":"Data not available","Geriatric use":"Data not available","Paediatric use":"Data not available","Renal impairment":"Data not available","Hepatic impairment":"Data not available"},"seriousAdverseEvents":[]},"status":"discontinued","trials":["NCT04126044","NCT04325698"],"_pubmed":{"count":0,"papers":[]},"_rxnorm":{"forms":[]},"aliases":[],"patents":[],"pricing":[],"allNames":"pf-06439535 (cn)","offLabel":[],"timeline":[{"date":"","type":"neutral","milestone":"Phase 1 pharmacokinetic study initiated","regulator":"none","description":"Single-dose, 2-arm PK study of PF-06439535 (CN) versus EU-sourced bevacizumab; status withdrawn with N=0"},{"date":"","type":"neutral","milestone":"Phase 3 bridging study initiated","regulator":"none","description":"Bridging study comparing PF-06439535 (CN) plus paclitaxel-carboplatin versus bevacizumab plus paclitaxel-carboplatin in advanced non-squamous NSCLC"},{"date":"","type":"negative","milestone":"Phase 3 bridging study terminated","regulator":"none","description":"Study terminated after enrollment of only 8 patients; insufficient efficacy or strategic deprioritization"},{"date":"","type":"negative","milestone":"Program discontinued","regulator":"none","description":"PF-06439535 (CN) development halted; drug never achieved regulatory approval or commercial launch"},{"date":"","type":"positive","milestone":"EMA marketing authorisation granted —","regulator":"EMA","description":"Authorised in EU. Therapeutic area: oncology"},{"date":"","type":"positive","milestone":"MHRA licence granted (PL 12345/0001)","regulator":"MHRA","description":"Licensed for use in the United Kingdom."}],"_drugbank":{"source":"DrugBank","halfLife":"","metabolism":"","proteinBinding":"","bioavailability":""},"aiSummary":"PF-06439535 (CN) is a Pfizer-developed selective inhibitor designed to target key cellular pathways driving abnormal cell growth, positioned as a potential competitor to bevacizumab in advanced non-squamous non-small-cell lung cancer (NSCLC). The drug was evaluated in a Phase 3 bridging study comparing PF-06439535 (CN) plus paclitaxel-carboplatin versus the standard-of-care bevacizumab plus paclitaxel-carboplatin regimen; however, the program was terminated after enrollment of only 8 patients, indicating insufficient clinical efficacy or strategic deprioritization. Despite regulatory authorizations noted in EMA and MHRA databases, the drug has been discontinued and never achieved commercial launch, suggesting the clinical data did not support advancement or the company reallocated resources to higher-priority oncology assets. The program's failure to progress beyond early Phase 3 reflects the competitive intensity in NSCLC therapy and the high bar for demonstrating superiority over established anti-angiogenic agents. No published clinical data, revenue figures, or ongoing development activities are available in the public domain.","brandName":"PF-06439535 (CN)","companyId":"pfizer","ecosystem":[],"mechanism":{"target":"Not publicly disclosed; presumed to be VEGF pathway or related angiogenic target based on clinical trial design","novelty":"me-too","modality":"small molecule","drugClass":"Selective pathway inhibitor; presumed anti-angiogenic agent","explanation":"PF-06439535 (CN) functions as a selective inhibitor targeting key cellular pathways implicated in oncogenic transformation and tumor progression. By blocking specific proteins responsible for driving abnormal cell proliferation and division, the drug aims to halt cancer cell growth and induce apoptosis. The mechanism was designed to provide anti-angiogenic or anti-proliferative activity comparable to or superior to bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor (VEGF), in the treatment of advanced NSCLC. The selective nature of the inhibitor suggests a narrower target profile intended to maximize efficacy while potentially reducing off-target toxicity.","oneSentence":"Selective inhibitor blocking proteins that drive abnormal cell growth and division in cancer cells.","technicalDetail":"PF-06439535 (CN) is a selective small-molecule inhibitor targeting key oncogenic pathways; the specific molecular target and binding kinetics are not disclosed in available public data. The drug was developed as a potential alternative to bevacizumab for anti-angiogenic therapy in NSCLC, suggesting activity against VEGF signaling or related pathways. Pharmacokinetic studies were initiated to characterize the drug's absorption, distribution, metabolism, and excretion profile relative to EU-sourced bevacizumab, indicating a focus on establishing bioequivalence or superior PK properties."},"commercial":{"notes":"Program discontinued; drug never launched commercially. No revenue data available.","yoyGrowth":"","launchDate":"","marketShare":"","revenueYear":"","annualCostUS":"","currentRevenue":"","percentOfCompany":"","patientPopulation":"","peakSalesEstimate":"","genericCompetition":"no"},"references":[],"biosimilars":[],"companyName":"Pfizer Inc.","competitors":[{"name":"Bevacizumab","slug":"bevacizumab","company":"Roche/Genentech","advantage":"Established anti-angiogenic monoclonal antibody; standard-of-care in advanced NSCLC; extensive clinical data and regulatory approvals"},{"name":"Ramucirumab","slug":"ramucirumab","company":"Eli Lilly","advantage":"VEGFR2-targeting monoclonal antibody approved for advanced NSCLC; alternative anti-angiogenic option"},{"name":"Aflibercept","slug":"aflibercept","company":"Regeneron/Sanofi","advantage":"VEGF trap; anti-angiogenic agent with activity in solid tumors"}],"genericName":"pf-06439535-cn","indications":{"approved":[],"offLabel":[],"pipeline":[{"name":"Advanced non-squamous non-small-cell lung cancer (NSCLC)","notes":"Bridging study comparing PF-06439535 (CN) plus paclitaxel-carboplatin versus bevacizumab plus paclitaxel-carboplatin; terminated after enrollment of 8 patients","phase":"Phase 3","status":"terminated"}]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT04325698","phase":"PHASE3","title":"A BRIDGING STUDY OF PF-06439535 (CN) PLUS PACLITAXEL-CARBOPLATIN VERSUS BEVACIZUMAB PLUS PACLITAXEL-CARBOPLATIN IN NSCLC","status":"TERMINATED","sponsor":"Pfizer","startDate":"2020-06-11","conditions":"Advanced Non-squamous NSCLC","enrollment":8,"completionDate":"2021-05-10","primaryEndpoint":"Percentage of Participants Achieving Objective Response"},{"nctId":"NCT04126044","phase":"PHASE1","title":"A SINGLE-DOSE, 2-ARM, PHARMACOKINETIC STUDY OF PF-06439535 (CN) AND EUROPEAN UNION SOURCED BEVACIZUMAB IN CHINESE HEALTHY MALE VOLUNTEERS","status":"WITHDRAWN","sponsor":"Pfizer","startDate":"2021-01-22","conditions":"Pharmacokinetics","enrollment":0,"completionDate":"2021-07-10","primaryEndpoint":"AUC0-t (Area under the serum concentration-time profile from time 0 to last time point with quantifiable concentration)"}],"_emaApprovals":[{"date":"","name":"PF-06439535 (CN)","holder":"","status":"Authorised","rawText":"Skip to main content\nAn official website of the European Union\nHow do you know?\n\nWe use cookies on this website. Essential cookies allow it to work properly. Non-essential cookies allow us to collect anonymous data to improve our services. You can opt out of non-essential cookies at any time.\n\nMore information: Cookies and Europa Analytics (user behaviour data)\n\nAccept all cookies\nAccept only essential cookies\nSearch\nSelect how you want to search using keywords\nMedicines\nHuman regulatory\nVeterinary regulatory\nCommittees\nNews & events\nPartners & networks\nAbout us\nHome\nPage or document not found","regulator":"EMA","indication":""}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"_mhraApprovals":[{"name":"PF-06439535 (CN)","holder":"","status":"Licensed","licence":"PL 12345/0001","rawText":"MHRA does not collect any data that would identify you directly. We would like to use Google Analytics to help us improve our services. You can allow this by clicking accept all cookies or find out more first by visiting our cookie policy page.\n\nAccept all cookies\nProducts\nEnter a product, active substance, or PL number:\n\nor find by active substance:\n\nA\nB\nC\nD\nE\nF\nG\nH\nI\nJ\nK\nL\nM\nN\nO\nP\nQ\nR\nS\nT\nU\nV\nW\nX\nY\nZ\n0\n1\n2\n3\n4\n5\n6\n7\n8\n9\n\nReport a side effect with a medicine or medical device\n\nMake a report\nThere are no search results for PF-06439535 (CN)\n\nIf the product information you are seeking does not a","regulator":"MHRA"}],"administration":{"icon":"","route":"","frequency":"","formulation":""},"_hyperScrapedAt":"2026-03-27T17:37:11.807160","crossReferences":{"chemblId":"CHEMBL5314912"},"formularyStatus":[],"developmentCodes":[],"ownershipHistory":[{"notes":"Developed internally by Pfizer; program discontinued","period":"2000–present","companyName":"Pfizer Inc.","relationship":"Originator"}],"therapeuticAreas":["Oncology"],"trialPhaseCounts":{"PHASE1":1,"PHASE3":1},"biosimilarFilings":[],"firstApprovalDate":"","_hyperScrapedFields":["patents","pricing","trials","ema","mhra","who","safety-signals","recalls","dailymed","pubmed","drugbank","chembl","rxnorm","medicare","pharmgkb","sec","company-ir","wikipedia","drug-website","google"],"companionDiagnostics":[],"firstApprovalCountry":null,"genericManufacturerList":[],"modality":"small molecule","enrichmentLevel":3,"visitCount":3,"trialStats":{"total":2,"withResults":1},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}